124 related articles for article (PubMed ID: 21795838)
21. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?
Reddy SV; Gupta SK
Singapore Med J; 2012 Mar; 53(3):e52-4. PubMed ID: 22434305
[TBL] [Abstract][Full Text] [Related]
22. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
23. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
Saad F; Eastham J
Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
[TBL] [Abstract][Full Text] [Related]
25. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
[TBL] [Abstract][Full Text] [Related]
26. [A Case of Disseminated Carcinomatosis of the Bone Marrow with Carcinoma of the Rectum Diagnosed by Disseminated Intravascular Coagulation].
Tanaka H; Matsutani S; Iwauchi T; Uchima Y; Miyamoto H; Okada T; Tsujio G; Kurihara S; Nagashima D; Hirakawa T; Hirata K; Morimoto J; Yamagata S; Takeuchi K
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2219-2221. PubMed ID: 33468913
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
28. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
29. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
Fulfaro F; Leto G; Badalamenti G; Arcara C; Cicero G; Valerio MR; Di Fede G; Russo A; Vitale A; Rini GB; Casuccio A; Intrivici C; Gebbia N
J Chemother; 2005 Oct; 17(5):555-9. PubMed ID: 16323446
[TBL] [Abstract][Full Text] [Related]
30. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy.
Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
Int J Mol Med; 2012 Oct; 30(4):896-904. PubMed ID: 22825050
[TBL] [Abstract][Full Text] [Related]
31. [A Case of Bisphosphonate-Related Osteonecrosis of the Jaw with Difficulty in Treatment].
Nakamura K; Fukumoto T; Fukui T; Sakatani T; Atsuta T; Kato T; Ito M; Inoue K; Terai A
Hinyokika Kiyo; 2016 Jan; 62(1):39-44. PubMed ID: 26932335
[TBL] [Abstract][Full Text] [Related]
32. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
[TBL] [Abstract][Full Text] [Related]
33. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
[TBL] [Abstract][Full Text] [Related]
34. [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
Hirayama Y; Ito Y; Kanamaru T; Sonoda T; Aoyama M; Nakamura N; Kawamura M
Gan To Kagaku Ryoho; 2011 Mar; 38(3):485-7. PubMed ID: 21403461
[TBL] [Abstract][Full Text] [Related]
35. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K
Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027
[TBL] [Abstract][Full Text] [Related]
36. [Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate].
Nishizawa S; Yamauchi T; Sawada Y
Hinyokika Kiyo; 2007 Dec; 53(12):891-5. PubMed ID: 18203529
[TBL] [Abstract][Full Text] [Related]
37. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
39. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
[TBL] [Abstract][Full Text] [Related]
40. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.
McQueen F; Lloyd R; Doyle A; Robinson E; Lobo M; Exeter M; Taylor WJ; Jones P; Reid IR; Dalbeth N
Ann Rheum Dis; 2011 Jun; 70(6):1091-4. PubMed ID: 21342915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
